Healthcare & pharmaceutical equity investment research - Page 2

Healthcare Insights

Market cap

Date (published)

thematic

Healthcare

26.01.23

Machine learning in drug development

thematic

Healthcare

13.06.23

ASCO 2023 key takeaways

Healthcare

thematic

04.01.24

Outlook for 2024: Life sciences – where has the conviction gone?

Latest

Healthcare | Update

26.04.24

Biodexa Pharmaceuticals — In a period of transition

Healthcare | Flash note

25.04.24

Creo Medical — NHS data validates Speedboat’s economic merit

Healthcare | Update

22.04.24

Basilea Pharmaceutica — Need for innovation against severe infections

Healthcare | Flash note

18.04.24

Ultimovacs — Steadfast commitment to UV1 progression

insight

Healthcare

18.05.23

Incannex Healthcare: Data opens path to treat anxiety

insight

Healthcare

09.02.23

February 2023 Edition of Edison Healthcare Insight

insight

Healthcare

30.01.23

VolitionRx: Commercializing the Nu.Q Vet Cancer Test: Webinar

insight

Healthcare

20.12.22

Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

insight

Healthcare

09.12.22

Healthcare Week 2023

insight

Healthcare

08.12.22

December 2022 edition of Edison Healthcare Insight

Analyst of the week

Soo Romanoff

Managing Director - Head of Content, Healthcare

sromanoff@edisongroup.com 020 3077 5700

Read latest

Equities

Region

Market cap

Oryzon Genomics (ORY)

Latest price

EUR1.98

▾ −0.04 (−1.88)

As at 25/04/2024

Market capitalisation: EUR124m

View equity

Flash note

Healthcare

09.04.24

Oryzon Genomics — FDA green light for SCLC combination trial

Flash note

Healthcare

05.04.24

Oryzon Genomics — Third time is a charm; INNOVATIVE SME Seal

Update

Healthcare

05.03.24

Oryzon Genomics — Approaching a period of inflection

See more
content on

Oryzon Genomics

OSE Immunotherapeutics (OSE)

Latest price

EUR5.60

▾ −0.04 (−0.71)

As at 25/04/2024

Market capitalisation: EUR122m

View equity

Flash note

Healthcare

18.04.24

OSE Immunotherapeutics — AbbVie deal clears antitrust hurdle

Flash note

Healthcare

12.04.24

OSE Immunotherapeutics — Funding accelerates Tedopi clinical development

Update

Healthcare

02.04.24

OSE Immunotherapeutics — Pipeline momentum builds into FY24

See more
content on

OSE Immunotherapeutics

Oxford Cannabinoid Technologies (OCTP)

Latest price

GBP0.00

— 0.00 (0.00)

As at 25/04/2024

Market capitalisation: GBP4m

View equity

Update

Healthcare

05.02.24

Oxford Cannabinoid Technologies — Early signs of revival in clinical activity

Flash note

Healthcare

12.10.23

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Update

Healthcare

12.09.23

Oxford Cannabinoid Technologies — Clinical headway rests on funding

See more
content on

Oxford Cannabinoid Technologies

Pharnext (ALPHA)

Latest price

EUR0.10

▾ 0.03 (42.86)

As at 25/04/2024

Market capitalisation: 1m

View equity

Flash note

TMT

22.04.24

Zalaris — Commencement of strategic review

Initiation

TMT

13.03.24

Zalaris — Simplifying HR and payroll solutions

Flash note

Healthcare

25.09.23

Pharnext — Potential licensing deals could add confidence

See more
content on

Pharnext

Recce Pharmaceuticals (RCE)

Latest price

AUD0.69

— 0.00 (0.00)

As at 25/04/2024

Market capitalisation: AUD140m

View equity

Update

Healthcare

26.03.24

Recce Pharmaceuticals — R&D advance (A$11.18m) extends runway

Update

Healthcare

20.02.24

Recce Pharmaceuticals — Supportive advancements on the pipeline

Team of Research Scientists Working On Computer, with Medical Equipment, Analyzing Blood and Genetic Material Samples with Special Machines in the Modern Laboratory.

Flash note

Healthcare

20.12.23

Recce Pharmaceuticals — Landmark commitment helps fund R&D costs

See more
content on

Recce Pharmaceuticals

Sareum Holdings (SAR)

Latest price

GBP0.26

▾ −4.25 (−13.93)

As at 25/04/2024

Market capitalisation: GBP28m

View equity

Update

TMT

25.04.24

Freelancer — AI to drive return to growth

Update

Healthcare

03.04.24

Sareum Holdings — A decisive period ahead for SDC-1801

Update

TMT

29.02.24

Freelancer — Primed for margin expansion

See more
content on

Sareum Holdings

SIGA Technologies (SIGA)

Latest price

USD8.64

▾ −0.02 (−0.23)

As at 25/04/2024

Market capitalisation: USD615m

View equity

Flash note

Healthcare

04.04.24

SIGA Technologies — Positive signals abound

Update

Healthcare

18.03.24

SIGA Technologies — Onwards and upwards with strong FY23

Flash note

Healthcare

23.01.24

SIGA Technologies — New captain to steer the ship

See more
content on

SIGA Technologies

Ultimovacs (ULTI)

Latest price

NOK6.93

▾ −0.65 (−8.58)

As at 25/04/2024

Market capitalisation: NOK239m

View equity

Flash note

Healthcare

18.04.24

Ultimovacs — Steadfast commitment to UV1 progression

Flash note

Healthcare

07.03.24

Ultimovacs — UV1 hits transitory roadblock with INITIUM top-line

Flash note

Healthcare

04.03.24

Ultimovacs — Peer-reviewed publication reiterates UV1’s potential

See more
content on

Ultimovacs

VolitionRx (VNRX)

Latest price

USD0.89

▾ 0.09 (11.25)

As at 25/04/2024

Market capitalisation: USD74m

View equity

Update

Healthcare

08.02.24

VolitionRx — Snaring sepsis, with early NETs detection

Update

Healthcare

17.01.23

VolitionRx — Vetting the pet health opportunity

Update

Healthcare

15.08.22

VolitionRX — Unravelling the web of NETs in sepsis

See more
content on

VolitionRx

Curated by Edison

singularityhub.com

The Next Step for AI in Biology Is to Predict How Proteins Behave in the Body

Healthcare

A new protein atlas can help turn static AI predictions of protein shapes into more fluid predictions of how proteins behave in the body.

Read article

www.genome.gov

The Cost of Sequencing a Human Genome

Healthcare

Estimated cost of sequencing the human genome over time since the Human Genome Project.

Read article

www.prnewswire.com

J.P. Morgan Launches New Life Sciences Private Capital Team Targeting Investments in Innovative Healthcare Companies

Healthcare

/PRNewswire/ -- J.P. Morgan Asset Management today announced the launch of a new life sciences private equity team, Life Sciences Private Capital. The new team...

Read article

insights.omnia-health.com

Leveraging nanotechnology to transform the disinfection industry

Healthcare

Co-founders of Kismet Technologies, Christina Drake and Shari Costantini, discuss how NanoRad, one of their flagship products, uses targeted application to kill a wide range of bacteria and viruses.

Read article

www.bain.com

2022 Healthcare Provider IT Report: Post-Pandemic Investment Priorities

Healthcare

As healthcare providers enter a new period of disruption, their software investment priorities present opportunities for vendors and investors.

Read article

Thematics

thematic

Healthcare

28.11.22

Drug delivery platforms

thematic

Healthcare

07.11.22

Oncology ABCs (part three) – thinking outside the box in women’s cancer

thematic

Healthcare

01.11.22

Neuroscience comeback

thematic

Consumer

05.10.22

IPO apocalypse

thematic

Healthcare

03.10.22

Oncology ABCs (part two) – vaccines: niche no longer

thematic

TMT

10.08.22

ESG, moving beyond the box tick

thematic

Healthcare

01.07.22

Oncology ABCs (part one) – a small-cap biopharma prospectus series

thematic

Healthcare

26.04.22

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Equities

Equities by Sector

Sectors

Investment Strategy

Latest

Equity strategy and market outlook – April 2024

Equity strategy and market outlook – March 2024

Equity strategy and market outlook – February 2024

Thematics

Latest

Listed private equity – Performing a balancing act

ConsumerWatch – At least someone loves me

MediaWatch – Rinse and repeat

Audiovisual

Latest

Checkit – executive interview

International Public Partnerships – executive interview

Unlocking US capital: Strategies for non-US-listed businesses

About Edison

About Edison

Careers

Healthcare

Pharnext

42.86%

Healthcare Insights

Machine learning in drug development

ASCO 2023 key takeaways

Outlook for 2024: Life sciences – where has the conviction gone?

Latest

Biodexa Pharmaceuticals — In a period of transition

Creo Medical — NHS data validates Speedboat’s economic merit

Basilea Pharmaceutica — Need for innovation against severe infections

Ultimovacs — Steadfast commitment to UV1 progression

Incannex Healthcare: Data opens path to treat anxiety

February 2023 Edition of Edison Healthcare Insight

VolitionRx: Commercializing the Nu.Q Vet Cancer Test: Webinar

Encouraging top-line data from Unyvero urinary tract infection (UTI) panel

Healthcare Week 2023

December 2022 edition of Edison Healthcare Insight

Analyst of the week

Equities

Oryzon Genomics (ORY)

EUR1.98

Oryzon Genomics — FDA green light for SCLC combination trial

Oryzon Genomics — Third time is a charm; INNOVATIVE SME Seal

Oryzon Genomics — Approaching a period of inflection

See morecontent on

OSE Immunotherapeutics (OSE)

EUR5.60

OSE Immunotherapeutics — AbbVie deal clears antitrust hurdle

OSE Immunotherapeutics — Funding accelerates Tedopi clinical development

OSE Immunotherapeutics — Pipeline momentum builds into FY24

See morecontent on

Oxford Cannabinoid Technologies (OCTP)

GBP0.00

Oxford Cannabinoid Technologies — Early signs of revival in clinical activity

Oxford Cannabinoid Technologies — Poised to progress to Phase II pending raise

Oxford Cannabinoid Technologies — Clinical headway rests on funding

See morecontent on

Pharnext (ALPHA)

EUR0.10

Zalaris — Commencement of strategic review

Zalaris — Simplifying HR and payroll solutions

Pharnext — Potential licensing deals could add confidence

See morecontent on

Recce Pharmaceuticals (RCE)

AUD0.69

Recce Pharmaceuticals — R&D advance (A$11.18m) extends runway

Recce Pharmaceuticals — Supportive advancements on the pipeline

Recce Pharmaceuticals — Landmark commitment helps fund R&D costs

See morecontent on

Sareum Holdings (SAR)

GBP0.26

Freelancer — AI to drive return to growth

Sareum Holdings — A decisive period ahead for SDC-1801

Freelancer — Primed for margin expansion

See morecontent on

SIGA Technologies (SIGA)

USD8.64

SIGA Technologies — Positive signals abound

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on

See more
content on